, 19 , 24 , 30 , 33 , 37 , 41 Prevalence of and Risk Factors for POI in Survivors Depending on patient factors, cancer diagnosis, and treatment exposures, the prevalence of POI in survivors of pediatric and AYA cancer ranged from 2.1% to 82
Search Results
Emma Gargus, Rebecca Deans, Antoinette Anazodo, and Teresa K. Woodruff
Michaela A. Dinan, Bradford R. Hirsch, and Gary H. Lyman
associated with an intermediate risk of FN in the range of 10% to 20%. For patients receiving myelosuppressive chemotherapy regimens with an intermediate risk of FN, guidelines recommend assessing patient-specific risk factors. Although many such factors have
William R. Kennedy, Christopher Tricarico, Prashant Gabani, Ashley A. Weiner, Michael B. Altman, Laura L. Ochoa, Maria A. Thomas, Julie A. Margenthaler, Souzan Sanati, Lindsay L. Peterson, Cynthia X. Ma, Foluso O. Ademuyiwa, and Imran Zoberi
-based NAC do not experience pCR, 8 , 9 and data are scarce regarding clinically identifiable prognostic risk factors in this cohort of patients who have residual disease after NAC. We recently identified risk factors for locoregional recurrence (LRR) in
Prashant Gabani, Emily Merfeld, Amar J. Srivastava, Ashley A. Weiner, Laura L. Ochoa, Dan Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Lindsay L. Peterson, Michael J. Naughton, Cynthia Ma, and Imran Zoberi
applied to obtain the final multivariable model. In patients who did not experience pCR, the Kaplan-Meier method was used to estimate whether those with multiple risk factors had an increased risk of LRR compared with those with a single risk factor
Kazzem Gheybi, Jue Jiang, Shingai B.A. Mutambirwa, Pamela X.Y. Soh, Zsofia Kote-Jarai, Weerachai Jaratlerdsiri, Rosalind A. Eeles, M.S. Riana Bornman, and Vanessa M. Hayes
significant risk factor for advanced PCa, with the lifetime risk of dying from PCa reported to increase by 2.3- to 5-fold for African Americans compared with all other ethnic groups within the United States. 5 For sub-Saharan Africa, PCa mortality rates are
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Breast cancer is the most commonly diagnosed cancer in American women, with an estimated 214,640 cases and 41,430 deaths occurring in 2006. Estimating breast cancer risk for individual women is difficult, and most breast cancers are not attributable to risk factors other than female gender and increased age. Developing effective strategies for reducing breast cancer incidence is also difficult because few existing risk factors are modifiable and some potentially modifiable risk factors have social implications. Nevertheless, effective breast cancer risk reduction agents and strategies, such as tamoxifen, raloxifene, and risk reduction surgery, have been identified. These guidelines were developed to help women at increased risk for breast cancer and their physicians apply individualized strategies to reduce breast cancer risk.
For the most recent version of the guidelines, please visit NCCN.org
Stefanie L. Thorsness, Azael Freites-Martinez, Michael A. Marchetti, Cristian Navarrete-Dechent, Mario E. Lacouture, and Emily S. Tonorezos
– 7 Although rarely a metastatic tumor, 8 NMSC can cause significant disfigurement and local destruction. Radiotherapy (RT) is a well-known risk factor for NMSC. 9 – 11 Retrospective studies have associated use of RT in the treatment of tinea
Benjamin E. Greer, Wui-Jin Koh, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, David K. Gaffney, Warner K. Huh, Daniel S. Kapp, John R. Lurain III, Lainie Martin, Mark A. Morgan, Robert J. Morgan Jr., David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr., Nelson Teng, and Fidel A. Valea
Clinical Practice Guidelines in Oncology [NCCN Guidelines] for Cervical Cancer Screening, in this issue; to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org ). 8 – 12 Other epidemiologic risk factors associated
Jashodeep Datta, Matthew T. McMillan, Eric K. Shang, Ronac Mamtani, Russell S. Lewis Jr, Rachel R. Kelz, Ursina Teitelbaum, John P. Plastaras, Jeffrey A. Drebin, Douglas L. Fraker, Giorgos C. Karakousis, and Robert E. Roses
criteria plateaued at approximately 40% per year between 2003 and 2007. Alarmingly, a substantial proportion of INT-0116–eligible patients (nearly 40% of cases per year) underwent surgery alone in 2007. 13 Risk factors for the omission of adjuvant
Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Jordan D. Berlin, J. Michael Berry, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Eric Rohren, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, William Small Jr., Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett
.6-fold for men and 1.5-fold for women from 1973-1979 to 1994-2000 2 (see Risk Factors, facing page). This manuscript summarizes the NCCN Clinical Practice Guidelines in Oncology for managing squamous cell anal carcinoma, which represents the most
